The shape of the pharmaceutical investment enterprise image is the key

Pharmaceutical agents pointed out that now they have entered a new investment market environment for pharmaceuticals, large areas and large circulation are inevitable, coupled with the state's pharmaceutical supervision and market regulation, the days of investment drug companies are not better than the previous achievements in brilliant models and processes It has changed. The current target market focus is to further subdivide the company's subdivision of pharmaceutical investment agency market, and subdivide the original subdivided market into multiple business units.

After all, we must start from the needs of agents. Only by discovering the urgent needs of the agents and providing them with solutions can the enthusiasm and stability of the dealers' products be promoted. To protect and purify the market, the actual situation of medicines in the market is that, on the one hand, a large number of products are homogenized, and the agents are unwilling to choose to operate; on the other hand, many dealers are constantly looking for suitable varieties. Operation, and a lot of the good varieties that we operate in are homogenized varieties that we seem to have low gold content.

According to the medical agent commissioner, the pharmaceutical investment enterprise should pay more attention to the core issue of how to realize that the product is transferred to the patient in the fastest time. After all, under the current pharmaceutical environment, relying solely on the power of one person to carry out large-scale capital investment in the development of the market, its risk is greater than ever before. Merchants can reduce their burden on the market by providing policy support in key products, key areas, and key customers. Investment companies and pharmaceutical agents collaborate to develop markets, enhance the anti-risk of agents, provide guarantees for market development of agents, facilitate the rapid transfer of products from manufacturers to patients, and ensure the soundness of product sales. cycle.

Today, the pharmaceutical market is becoming increasingly rational. Some units still hold a lucky mood. They do not have a good model but insist that they have advanced models. They are trying to amass financial resources through the use of medicine to attract goods. By standardizing the investment promotion process of pharmaceuticals and improving the overall quality of the industry, it is possible to effectively distinguish between excellent pharmaceutical investment enterprises and disadvantaged pharmaceutical investment enterprises in the industry, good products and products with no special characteristics, thereby driving out those companies that are in troubled waters. Only in this way can the image of the industry be re-established, and the trust between the enterprises can be established again.

In addition, drug dealers pointed out that medical agents have passed the era of calling and business. In today's social situation, doing investment in medicine requires more thoughts. Various investment companies are constantly researching and developing solutions. The most up to nothing is nothing more than a strategic article, but there are many companies that have overlooked some minor issues. For example, some of the most basic and basic issues are often overlooked by these companies. They do not know that many pharmaceutical investment companies are because they are in their view. Frustrated by unimportant issues.